Previous 10 | Next 10 |
PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels PITTSBURGH , Dec. 3, 2020 /PRNewswire/ -- PANTHERx ® Rare Pharmacy an...
Alnylam Pharmaceuticals (ALNY) has completed the enrollment of 21 subjects in a Phase 3 clinical trial, ILLUMINATE-C, evaluating RNAi therapeutic lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1), a rare disorder caused by the buildup of oxalate, normally filtered th...
Orsini Specialty Pharmacy Expands Partnership With Alnylam® Pharmaceuticals As A Limited Distribution Partner For OXLUMO™ (lumasiran) ELK GROVE VILLAGE, Ill. , Dec. 3, 2020 /PRNewswire/ -- Orsini Specialty Pharmacy, a leader in rare diseases and gene the...
- Topline Results Expected in Mid-2021 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its ILLUMINATE-C Phase 3 study of lumasiran, an RNAi therapeutic targeting hydr...
Could These Be The Top Biotech Stocks To Watch Now? The race for a coronavirus vaccine has benefitted most top biotech stocks so far. In turn, this has created an intense competition to vaccinate the world amongst a wide array of biotech companies. Moreover, the recent news of P...
We don't know how many different rare diseases there are right now that need better treatment options, but Alnylam (NASDAQ: ALNY) is chipping away at the stone with a jackhammer. The company successfully launched its first rare disease drug last spring and already expects a fourth n...
Revenue is growing at a high percentage rate, but on a small base. Heavy investment in R&D will pay off as the decade progresses. If inclisiran is approved, revenue should ramp substantially in 2021. FDA approved Oxlumo for primary hyperoxaluria on November 24. For f...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43 rd Nasdaq Virtual Investor Conference on Friday, December 4, 2020 at 11:00 am ET. A live audio webcast of the presen...
Alnylam (ALNY) entered a new framework for value-based agreements, or VBAs, designed to help people with primary hyperoxaluria type 1, or PH1, gain access to Oxlumo.Recently, he FDA has approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH...
- Expedited Access to OXLUMO Aims to Support Children and Adults Living with PH1 who Face Inevitable Disease Progression and Irreversible Kidney Damage in the Absence of New Treatment Options - - New Value-Based Agreement Framework Includes an Innovative Patient Need Adjustmen...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...